COM.04250
0 followers
0 Likes
Good morning!!
I have a question about comparability of methods. Due to my facility switching my blood gases analysis from the i-STAT, I am only using my i-STAT for ACT testing and backup for cTnI. I have no issue on doing verification for the cTnI but we have never done a 6 month comparison on ACT. Is there any of you that do the bi-annual comparison of your ACT methods on the i-STAT? If so, are you just following the linearity procedure in the i-STAT manual or another method.
Thanks!!
1 Reply
Reply
Subgroup Membership is required to post Replies
Join POCT Listserv now
Suggested Posts
| Topic | Replies | Likes | Views | Participants | Last Reply |
|---|---|---|---|---|---|
| iSTAT in NICU -chem 8, CG4 | 5 | 0 | 259 | ||
| Rotem Sigma Validation Help | 1 | 0 | 104 | ||
| Hemochron Sig Elite use outside of manufacturer temperature range | 2 | 0 | 172 |
The only patient comparison that I perform for our ISTAT for the ACT is an ISTAT to ISTAT comparison. We have 2 ISTATs that perform ACT. Since the Lab does not perform ACT, the staff are required,
twice a year, to run 5 patients on each ISTAT and then I compare the results. The results for each patient should match within an acceptable limit.
Kathy Andrews
MLT, RT
Point of Care Coordinator / Coordinatrice des Analyses Hors Laboratoire
Moncton & Miramichi Area /
Régions de Moncton et Miramichi
Horizon Health Network / Reseau de Sante Horizon
Tel: (506)-857-5315 Fax: (506) 857-5325
kathy.andrews@horizonnb.ca
“Be the change that you wish to see in the world.”
― Mahatma
Gandhi
From: Cassie Nobles via POCT Listserv (Groupsite) <users+1233115@poct.groupsite.com>
Sent: April 14, 2020 11:03 AM
To: Andrews, Kathy (LAB) (HorizonNB) <Kathy.Andrews@HorizonNB.ca>
Subject: [POCT Listserv] COM.04250
ATTENTION! External email / courriel externe.
------- Horizon Health Network Disclaimer -------
This e-mail communication (including any or all attachments) is intended
only for the use of the person or entity to which it is addressed and may
contain confidential and/or privileged material. If you are not the intended
recipient of this e-mail, any use, review, retransmission, distribution,
dissemination, copying, printing, or other use of, or taking of any action in
reliance upon this e-mail, is strictly prohibited. If you have received this
e-mail in error, please contact the sender and delete the original and any
copy of this e-mail and any printout thereof, immediately. Your
co-operation is appreciated.
Le présent courriel (y compris toute pièce jointe) s'adresse uniquement à
son destinataire, qu'il soit une personne ou un organisme, et pourrait
comporter des renseignements privilégiés ou confidentiels. Si vous n'êtes
pas le destinataire du courriel, il est interdit d'utiliser, de revoir, de
retransmettre, de distribuer, de disséminer, de copier ou d'imprimer ce
courriel, d'agir en vous y fiant ou de vous en servir de toute autre façon.
Si vous avez reçu le présent courriel par erreur, prière de communiquer
avec l'expéditeur et d'éliminer l'original du courriel, ainsi que toute copie
électronique ou imprimée de celui-ci, immédiatement. Nous sommes
reconnaissants de votre collaboration.